These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 22871496

  • 1. Pharmacological targeting of mammalian target of rapamycin inhibits ovarian granulosa cell tumor growth.
    Rico C, Laguë MN, Lefèvre P, Tsoi M, Dodelet-Devillers A, Kumar V, Lapointe E, Paquet M, Nadeau MÈ, Boerboom D.
    Carcinogenesis; 2012 Nov; 33(11):2283-92. PubMed ID: 22871496
    [Abstract] [Full Text] [Related]

  • 2. Alterations of hypoxia-induced factor signaling pathway due to mammalian target of rapamycin (mTOR) suppression in ovarian clear cell adenocarcinoma: in vivo and in vitro explorations for clinical trial.
    Hirasawa T, Miyazawa M, Yasuda M, Shida M, Ikeda M, Kajiwara H, Matsui N, Fujita M, Muramatsu T, Mikami M.
    Int J Gynecol Cancer; 2013 Sep; 23(7):1210-8. PubMed ID: 23899586
    [Abstract] [Full Text] [Related]

  • 3. Synergistic effects of Pten loss and WNT/CTNNB1 signaling pathway activation in ovarian granulosa cell tumor development and progression.
    Laguë MN, Paquet M, Fan HY, Kaartinen MJ, Chu S, Jamin SP, Behringer RR, Fuller PJ, Mitchell A, Doré M, Huneault LM, Richards JS, Boerboom D.
    Carcinogenesis; 2008 Nov; 29(11):2062-72. PubMed ID: 18687666
    [Abstract] [Full Text] [Related]

  • 4. Dysregulation of WNT/CTNNB1 and PI3K/AKT signaling in testicular stromal cells causes granulosa cell tumor of the testis.
    Boyer A, Paquet M, Laguë MN, Hermo L, Boerboom D.
    Carcinogenesis; 2009 May; 30(5):869-78. PubMed ID: 19237610
    [Abstract] [Full Text] [Related]

  • 5. Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids.
    Zatelli MC, Minoia M, Martini C, Tagliati F, Ambrosio MR, Schiavon M, Buratto M, Calabrese F, Gentilin E, Cavallesco G, Berdondini L, Rea F, degli Uberti EC.
    Endocr Relat Cancer; 2010 Sep; 17(3):719-29. PubMed ID: 20554786
    [Abstract] [Full Text] [Related]

  • 6. Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.
    Zhao MY, Auerbach A, D'Costa AM, Rapoport AP, Burger AM, Sausville EA, Stass SA, Jiang F, Sands AM, Aguilera N, Zhao XF.
    Clin Cancer Res; 2009 Mar 01; 15(5):1708-20. PubMed ID: 19223503
    [Abstract] [Full Text] [Related]

  • 7. 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model.
    Aide N, Kinross K, Cullinane C, Roselt P, Waldeck K, Neels O, Dorow D, McArthur G, Hicks RJ.
    J Nucl Med; 2010 Oct 01; 51(10):1559-64. PubMed ID: 20847160
    [Abstract] [Full Text] [Related]

  • 8. eIF4B is a convergent target and critical effector of oncogenic Pim and PI3K/Akt/mTOR signaling pathways in Abl transformants.
    Chen K, Yang J, Li J, Wang X, Chen Y, Huang S, Chen JL.
    Oncotarget; 2016 Mar 01; 7(9):10073-89. PubMed ID: 26848623
    [Abstract] [Full Text] [Related]

  • 9. Anti-tumor effect of the mammalian target of rapamycin inhibitor everolimus in oral squamous cell carcinoma.
    Naruse T, Yanamoto S, Yamada S, Rokutanda S, Kawakita A, Kawasaki G, Umeda M.
    Pathol Oncol Res; 2015 Jul 01; 21(3):765-73. PubMed ID: 25682238
    [Abstract] [Full Text] [Related]

  • 10. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.
    Panwalkar A, Verstovsek S, Giles FJ.
    Cancer; 2004 Feb 15; 100(4):657-66. PubMed ID: 14770419
    [Abstract] [Full Text] [Related]

  • 11. MiR-15/16 complex targets p70S6 kinase 1 and controls cell proliferation in MDA-MB-231 breast cancer cells.
    Janaki Ramaiah M, Lavanya A, Honarpisheh M, Zarea M, Bhadra U, Bhadra MP.
    Gene; 2014 Dec 01; 552(2):255-64. PubMed ID: 25261849
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. mTORC1 inhibitors suppress meningioma growth in mouse models.
    Pachow D, Andrae N, Kliese N, Angenstein F, Stork O, Wilisch-Neumann A, Kirches E, Mawrin C.
    Clin Cancer Res; 2013 Mar 01; 19(5):1180-9. PubMed ID: 23406776
    [Abstract] [Full Text] [Related]

  • 14. The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer.
    Meyer LA, Slomovitz BM, Djordjevic B, Westin SN, Iglesias DA, Munsell MF, Jiang Y, Schmandt R, Broaddus RR, Coleman RL, Galbincea JM, Lu KH.
    Int J Gynecol Cancer; 2014 May 01; 24(4):713-7. PubMed ID: 24651628
    [Abstract] [Full Text] [Related]

  • 15. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer.
    Mabuchi S, Altomare DA, Connolly DC, Klein-Szanto A, Litwin S, Hoelzle MK, Hensley HH, Hamilton TC, Testa JR.
    Cancer Res; 2007 Mar 15; 67(6):2408-13. PubMed ID: 17363557
    [Abstract] [Full Text] [Related]

  • 16. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
    François RA, Maeng K, Nawab A, Kaye FJ, Hochwald SN, Zajac-Kaye M.
    J Natl Cancer Inst; 2015 Aug 15; 107(8):. PubMed ID: 25971297
    [Abstract] [Full Text] [Related]

  • 17. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids.
    Gagliano T, Bellio M, Gentilin E, Molè D, Tagliati F, Schiavon M, Cavallesco NG, Andriolo LG, Ambrosio MR, Rea F, Degli Uberti E, Zatelli MC.
    Endocr Relat Cancer; 2013 Aug 15; 20(4):463-75. PubMed ID: 23653462
    [Abstract] [Full Text] [Related]

  • 18. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.
    Wanner K, Hipp S, Oelsner M, Ringshausen I, Bogner C, Peschel C, Decker T.
    Br J Haematol; 2006 Sep 15; 134(5):475-84. PubMed ID: 16856892
    [Abstract] [Full Text] [Related]

  • 19. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Chen X, Zhao M, Hao M, Sun X, Wang J, Mao Y, Zu L, Liu J, Shen Y, Wang J, Shen K.
    Mol Cancer Res; 2013 Oct 15; 11(10):1269-78. PubMed ID: 23814023
    [Abstract] [Full Text] [Related]

  • 20. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
    Ewald F, Grabinski N, Grottke A, Windhorst S, Nörz D, Carstensen L, Staufer K, Hofmann BT, Diehl F, David K, Schumacher U, Nashan B, Jücker M.
    Int J Cancer; 2013 Nov 15; 133(9):2065-76. PubMed ID: 23588885
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.